Effect of Beetroot Supplementation on Cardiometabolic Risk Factors in Individuals with Prediabetes: Study Protocol for a Randomized Controlled Trial
Abstract
Background: Beetroot, rich in bioactive compounds, is linked to improved blood pressure, exercise performance, and glucose metabolism. Its potential benefits make it a promising dietary option for prediabetes, a condition with elevated blood sugar levels increasing the risk of type 2 diabetes. Aim: This trial is designed to examine the overall effect of consuming beetroot powder on cardiometabolic risk factors in individuals with prediabetes. Methods: In this double-blind, randomized, placebo-controlled trial, 44 individuals with prediabetes will be randomly assigned (1:1 ratio via a computer-generated block randomization sequence) to receive either 14 g/d beetroot powder or a matched placebo daily for 12 weeks. The sample size provided 80% power to detect a 25.5 mg/dl (SD: 29 mg/dl) difference in fasting glucose level at a 5% significance level. The primary outcome is glycemic control (fasting plasma glucose, fasting insulin, 2-hour blood glucose, hemoglobin A1C (HbA1c), and insulin resistance indices). Lipid parameters, liver enzymes, kidney function, and oxidative stress markers will be assessed as secondary outcomes. The measurements will be done at baseline and after 12 weeks of intervention. Results: Changes in glycemic and secondary cardiometabolic outcomes will be compared between the beetroot and placebo groups after 12 weeks using intention-to-treat analyses. Conclusion: This trial will determine whether beetroot supplementation improves glycemic control and cardiometabolic risk factors in adults with prediabetes.
Related
- Fruit Smoothie Supplementation and Inflammatory Biomarkers in Individuals Receiving Opioid Agonist Therapy: A Multicenter Randomized Controlled Trial
- Differential physical activity responses to diabetes risk reduction interventions according to prediabetes phenotype in at-risk individuals: pooled analysis from three randomised controlled trials
- PlanetDiet: Sustainable diets and cardiometabolic health, study protocol for a six-month parallel-group randomized controlled trial in middle-aged adults at cardiovascular risk
- The cooking for health optimization and disease prevention (CHOP) trial for improving cardiometabolic and mental health among older adults: study protocol for a randomized controlled trial
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
BibTeX
@article{hosseini2026effect,
title = {{Effect of Beetroot Supplementation on Cardiometabolic Risk Factors in Individuals with Prediabetes: Study Protocol for a Randomized Controlled Trial}},
author = {Elham Hosseini and Zeinab Mokhtari and Saharnaz Rahpeyma and Mansour Siavash},
journal = {International Journal of Preventive Medicine},
year = {2026},
month = sep,
doi = {10.4103/ijpvm.ijpvm_76_25},
url = {https://doi.org/10.4103/ijpvm.ijpvm_76_25},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Effect of Beetroot Supplementation on Cardiometabolic Risk Factors in Individuals with Prediabetes: Study Protocol for a Randomized Controlled Trial
AU - Elham Hosseini
AU - Zeinab Mokhtari
AU - Saharnaz Rahpeyma
AU - Mansour Siavash
PY - 2026
DA - 2026/09/01
JO - International Journal of Preventive Medicine
DO - 10.4103/ijpvm.ijpvm_76_25
UR - https://doi.org/10.4103/ijpvm.ijpvm_76_25
AB - Background: Beetroot, rich in bioactive compounds, is linked to improved blood pressure, exercise performance, and glucose metabolism. Its potential benefits make it a promising dietary option for prediabetes, a condition with elevated blood sugar levels increasing the risk of type 2 diabetes. Aim: This trial is designed to examine the overall effect of consuming beetroot powder on cardiometabolic risk factors in individuals with prediabetes. Methods: In this double-blind, randomized, placebo-controlled trial, 44 individuals with prediabetes will be randomly assigned (1:1 ratio via a computer-generated block randomization sequence) to receive either 14 g/d beetroot powder or a matched placebo daily for 12 weeks. The sample size provided 80% power to detect a 25.5 mg/dl (SD: 29 mg/dl) difference in fasting glucose level at a 5% significance level. The primary outcome is glycemic control (fasting plasma glucose, fasting insulin, 2-hour blood glucose, hemoglobin A1C (HbA1c), and insulin resistance indices). Lipid parameters, liver enzymes, kidney function, and oxidative stress markers will be assessed as secondary outcomes. The measurements will be done at baseline and after 12 weeks of intervention. Results: Changes in glycemic and secondary cardiometabolic outcomes will be compared between the beetroot and placebo groups after 12 weeks using intention-to-treat analyses. Conclusion: This trial will determine whether beetroot supplementation improves glycemic control and cardiometabolic risk factors in adults with prediabetes.
SN - 2008-7802
SN - 2008-8213
ER -